Table 2. Methodology used to measure fasting circulating glicentin concentrations in human.

Detection method	Sample	Population	Glicentin concentration (pmol/L)		References
			Median (interquartile range)	Mean ± standard error mean
Commercialized ELISA technique (Merck- Millipore®) - Inter-assay variation: < 15% - Intra-assay variation: < 10%	Plasma	Patients who had acute pancreatitis (N = 83)	6.2 (3.0 - 16.7)	-	Pendharkar et al. (45)
Commercialized ELISA technique (Mercodia®) - Detection limit: 3 pmol/L - Inter-assay variation: < 10.8% - Intra-assay variation: < 8%	Plasma	Lean adolescents (N = 19) Adolescents with obesity and normal glucose tolerance (N = 23) Adolescents with obesity and impaired glucose tolerance (N = 19) Adolescents with obesity and type 2 diabetes (N = 4)	17.6 (13 – 25) 23.6 (17.7 – 32.8) 18.2 (8.6 – 21.8) 15.1 (13.3 – 18)	-	Manell et al. (42)
	Serum	Lean adults (N = 52) Adults with severe or morbid obesity (N = 39)	24 (18 - 38) 12 (7.6 – 17)	-	Raffort et al. (44)
		Adults with severe or morbid obesity before Roux-en-Y Gastric Bypass (RYGB) surgery (N = 18) Adults 12 months after RYGB surgery (N = 18) Adults with severe or morbid obesity before Laparoscopic Sleeve Gastrectomy (LSG)† surgery (n= 12) Adults 12 months after LSG surgery (n= 12)	-	14 ± 3.6 19.7 ± 2.7 12.5 ± 1.4 16.4 ± 1.8	Raffort et al. (43)
Non-commercialized sandwich ELISA - Detection limit: 3.8 pmol/L - Inter-assay variation: < 8% - Intra-assay variation: < 5%	Plasma	Diabetic patients (N = 119) Controls (N = 6)	-	19.7 ± 2.1 18.6 ± 4.7	Naito et al. (39)
		Very-low-birthweight infants (N = 21)	NV	NV	Shimizu et al. (41)
		Children (N = 119)	NV	NV	Tadokoro et al. (40)
Non-commercialized radioimmunoassay and chromatography	Plasma	Non insulin-dependent diabetic patients (N = 8) Controls (N =8)	NV	NV	Orskov et al. (38)
RYGB: Roux-en-Y Gastric Bypass. LSG: Laparoscopic Sleeve Gastrectomy. NV - no exact values.